Quantcast

Latest Valeant Pharmaceuticals Stories

2014-07-10 12:29:53

LAVAL, Quebec, July 10, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle S.A, which recently completed its acquisition of Galderma. "We are pleased to complete the divestiture of our products to a company that is...

2014-07-08 08:30:55

LAVAL, Quebec, July 8, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of PreCision Dermatology, Inc. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, and Clindagel. About Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty...

2014-06-25 08:30:57

LAVAL, Quebec, June 25, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced the filing of a preliminary proxy statement for a special meeting of shareholders, at which Valeant shareholders will consider and vote upon, among other things, a proposal to approve the issuance of Valeant common shares in connection with an acquisition of Allergan, Inc. ("Allergan") (NYSE: AGN). Valeant commenced an exchange offer for the common...

2014-06-23 08:28:35

LAVAL, Quebec, June 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that, as promised, it has posted fact-based answers to refute misleading assertions made by Allergan, Inc. (NYSE: AGN) in its June 10(th) presentation. Valeant's presentation is posted at http://valeant.com/about/valeant-allergan. Valeant intends to provide future updates to this document as appropriate. About Valeant Pharmaceuticals International, Inc. Valeant...

2014-06-18 12:37:20

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharma_leader_series_top_25_ophthalmic_drug_manufacturers_2014_2024.html Report DetailsNew study shows you commercial prospects for leading eye drug producersWhat does the future hold for top companies in the pharma ophthalmics industry? Visiongain's brand new report...

2014-06-18 12:36:30

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Orphan Drugs for CNS Diseases: R&D and Market 2014-2024http://www.reportbuyer.com/pharma_healthcare/therapeutic/orphan_drugs_cns_diseases_rd_market_2014_2024.html Report DetailsUncommon nerve disorders - new study explains technological and commercial prospectsWhat's the future of medicines for rare central nervous system (CNS) disorders? Visiongain's new report gives you predictions...

2014-06-18 12:32:37

LAVAL, Quebec, June 18, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30(th) proposal directly to Allergan stockholders. Under the terms of the offer, Allergan stockholders would be able to elect to exchange each of their Allergan shares for $72.00 in cash and 0.83 Valeant common shares, or an amount of...

2014-06-16 08:29:21

LAVAL, Quebec, June 16, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Restylane® Silk Injectable Gel with 0.3% Lidocaine, a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. "We are pleased to have received marketing clearance from...

2014-06-13 20:21:55

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the...

2014-06-13 12:25:00

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a fact-based presentation to refute recent misleading assertions made by Allergan, Inc. (NYSE: AGN) and others, as well as answer additional investor questions, on June 17, 2014. Conference Call and Webcast Information The Company will host a conference call and a live Internet webcast along with a slide presentation at 8:00 a.m. ET (5:00 a.m....


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related